Clinical study of selegiline hydrochloride (FP OD tablet 2.5) to flexion of spine in Parkinson's disease.

Trial Profile

Clinical study of selegiline hydrochloride (FP OD tablet 2.5) to flexion of spine in Parkinson's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Selegiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2015 Status changed from active, no longer recruiting to completed, according to University Hospital Medical Information Network - Japan record.
    • 15 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 19 Jan 2014 According to University Hospital Medical Information Network - Japan record, Planned End Date changed from 19 Jul 2013 to 19 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top